drugset
drugset / Trial / NCT07483554

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

NCT07483554 ↗

Phase 2 Recruiting 389 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.

Timeline

Start
2026-04-20
Primary completion
2028-03-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI343 Monoclonal antibody — Intravenous
Background Gemcitabine Small molecule — Intravenous
Background Paclitaxel Small molecule — Intravenous

Indications

gastroesophageal junction adenocarcinoma pancreatic ductal adenocarcinoma